COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients: A Prospective Observational Registry
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Heather Garrett, M.D.
- Phone Number: 314-454-5206
- Email: hvgarrett@wustl.edu
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Principal Investigator:
- Heather Garrett, M.D.
-
Sub-Investigator:
- Debbie Bennett, M.D.
-
Sub-Investigator:
- Christina Doherty, M.D.
-
Sub-Investigator:
- Tabassum Ahmad, M.D.
-
Sub-Investigator:
- Jingqin Luo, Ph.D.
-
Sub-Investigator:
- Katherine Clifton, M.D.
-
Sub-Investigator:
- Julie Margenthaler, M.D.
-
Contact:
- Heather Garrett, M.D.
- Phone Number: 314-454-5206
- Email: hvgarrett@wustl.edu
-
Sub-Investigator:
- Mariya Kristeva, M.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Eligibility Criteria:
- Diagnosis of breast cancer.
- Mass must be visible on ultrasound and > 5 mm from skin.
Not undergoing surgery, because:
- Patient has a medical condition that would not allow sedation or general anesthesia
- Surgery is not clinically indicated due to unresectable and/or metastatic disease
- Surgery is not clinically indicated for another reason
- Patient declines surgery
- At least 18 years old.
- Able to understand and willing to sign an IRB-approved written informed consent document.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cryoablation
Following pre-procedural imaging evaluation, patients will receive ultrasound-guided percutaneous cryoablation as part of their routine treatment of their breast cancer.
Follow up imaging (if tolerated) will be performed at 6 months and 12 months and annually thereafter for until 3 years post-procedure.
Data will be collected on patient demographics, disease characteristics, treatment, treatment complications, follow-up imaging, response (for 3 years post-procedure), and quality of life.
|
Takes place at single time point.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients who are free of serious treatment related complications per CTCAE v 5.0
Time Frame: Through 3 year follow-up
|
Through 3 year follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients who demonstrate progression-free survival (PFS)
Time Frame: At 3 year follow-up
|
At 3 year follow-up
|
|
Proportion of patients who demonstrate disease-free survival (DFS)
Time Frame: At 3 year follow-up
|
At 3 year follow-up
|
|
Proportion of patients who demonstrate overall survival (OS)
Time Frame: At 3 year follow-up
|
At 3 year follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Heather Garrett, M.D., Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 202307067
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.